孟鲁司特钠治疗儿童毛细支气管炎临床观察

Clinical effect of Montelukast Sodium in treatment of children with bronchiolitis

目的研究孟鲁司特钠治疗儿童毛细支气管炎的临床效果。方法选择2013年9月～2014年3月在房山区良乡医院住院的毛细支气管炎患儿94例，按照给药方法不同分为观察组（n=49）和对照组（n=45）两组。对照组给予常规治疗方法，观察组在对照组的基础上加用孟鲁司特钠片口服。观察比较两组患儿临床疗效、症状消失时间以及不良反应。结果治疗后两组患儿的临床疗效均有明显改善，观察组的总有效率（93．88％）显著高于对照组（82．22％）（P〈0．05）。治疗后，观察组嗜酸粒细胞阳离子蛋白（ECP）水平[（9．02±2．37）μg/L]明显高于对照组[（5．17±1．09）μg/L]，差异有统计学意义（P〈0．05）；与治疗前相比，治疗后观察组和对照组患儿白介素8（IL-8）水平[（44．68±11．23）μg/L比（31．19±9．28）μg/L，（50．27±13．30）μg/L比（28．54±7．37）μg/L]均明显下降（P〈0．05），但组间比较差异均无统计学意义（P〉0．05）。治疗后观察组患儿咳嗽、喘憋、呼吸困难、肺部哮鸣音消失时间以及住院天数[（5．14±1．16）、（4．28±1．31）、（3．66±1．09）、（4．31±1．47）、（7．85±2．03）d1均显著少于对照组[（7．25±1．83）、（6．09±1．501、（5．03±1．33）、（6．67±1．72）、（11．67±2．53）d]，差异均有统计学意义（均P〈0．05）；两组患儿在治疗期间没有发生明显的不良反应。结论孟鲁司特钠口服治疗小儿毛细支气管炎效果显著，且未见不良反应，值得临床推广和使用。

Objective To study the effect of Montelukast Sodium in treatment of children with bronchiolitis. Methods A total of 94 cases of children with bronchiolitis in Liangxiang Hospital in Fangshan District of Beijing City from September 2013 to March 2014 were selected and divided into observation group （n=49） and control group （n=45）, according to different therapeutic schemes. And the control group was given the general methods of treatment, and the observation group was based on the same treatment plus Montelukast Sodium Tablets. The clinical effect, symptoms dis- appear time and the incidence of adverse reactions were observed and compared between the two groups. Results The clinical effect between the two groups improved significantly after treatment, the total effective rate in the observation group （93.88%） was higher than that in the control group （82.22%） （P 〈 0.05）. ECP levels in the observation group [（9.02±2.37） μg/L] was higher than that in the control group [（5.17±1.09） μg/L] （P 〈 0.05）; IL-8 levels between the two groups after treatment [（44.68±11.23） μg/L vs （31.19±9.28） μg/L, （50.27±13.30） μg/L vs （28.54±7.37） μg/L] were lower than those before the treatment （P 〈 0.05）, but there was no significant difference in two groups after treatment （P 〉 0.05）. The symptoms disappear time in the observation group [（5.14±1.16）, （4.28±1.31）, （3.66±1.09）, （4.31±1.47）, （7.85± 2.03） d] were less than those in control group [（7.25±1.83）, （6.09±1.50）, （5.03±1.33）, （6.67±1.72）, （11.67±2.53） d] after treatment （P 〈 0.05）. There were no obvious adverse reactions between the two groups during the treatment. Conclusion The curative effect of Montelukast Sodium Tablets orally in treating capillary bronchitis is significant, with less ad- verse reactions, which is worthy of clinical promotion and application.